Online inquiry

IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14053MR)

This product GTTS-WQ14053MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Paroxysmal nocturnal hemoglobinuria (PNH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14053MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13481MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ11008MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCLA-117
GTTS-WQ11554MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MGA031
GTTS-WQ4234MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB029
GTTS-WQ9591MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ3152MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ2646MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 592
GTTS-WQ12022MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MM-302
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW